This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About DURECT Stock (NASDAQ:DRRX) Get DURECT alerts:Sign Up Key Stats Today's Range$1.91▼$1.9150-Day Range$1.85▼$1.9652-Week Range$0.48▼$2.64VolumeN/AAverage Volume699,433 shsMarket Capitalization$59.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview DURECT Corporation (NASDAQ: DRRX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, small-molecule therapeutics in areas of high unmet medical need. Founded in 1998 and headquartered in California, DURECT pursues programs in inflammatory, fibrotic, and central nervous system disorders. The company’s research is supported by a proprietary drug delivery platform designed to optimize the release profiles and bioavailability of its drug candidates. The company’s leading clinical asset, DUR-928, is an endogenous regulator being evaluated for the treatment of liver diseases, kidney disorders, and acute organ injury. Another key program, POSIMIR, is an investigational, long-acting local analgesic formulation intended to manage postsurgical pain. DURECT also maintains a robust preclinical pipeline that leverages its small-molecule chemistry expertise to target novel pathways in autoimmune conditions and oncology. Beyond its internal pipeline, DURECT commercializes RELiZORB®, an immobilized lipase cartridge designed to improve fat absorption in patients receiving enteral nutrition, and it has partnered with pharmaceutical companies to license its drug delivery technologies. The IntraPhase™ controlled-release platform is used to develop injectable depot formulations, while its ALZET® osmotic pumps are utilized by researchers worldwide for sustained compound delivery in preclinical studies. Under the leadership of President and CEO Andrew B. Allen, DURECT collaborates with academic institutions, biotechnology firms, and pharmaceutical partners to advance both its therapeutic candidates and delivery systems. The company’s global reach extends through strategic alliances and licensing agreements aimed at accelerating clinical development and expanding access to its proprietary technologies.AI Generated. May Contain Errors. Read More Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRRX Stock News HeadlinesDurect Merges with Bausch Health, Delists from NasdaqSeptember 11, 2025 | tipranks.comBausch Health announces extension of Durect tender offerAugust 26, 2025 | msn.comJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morgan Stanley, and the largest funds begin presenting SpaceX's S-1 to clients. Buried in that filing is a small, publicly traded company that builds critical power infrastructure Musk's Colossus can't operate without. Right now it trades like a sleepy industrial stock. Dylan Jovine has the ticker and is releasing it before the roadshow begins.May 24 at 1:00 AM | Behind the Markets (Ad)DURECT Corporation Stock (DRRX) Opinions on Potential Acquisition by Bausch HealthAugust 22, 2025 | quiverquant.comQDurect, Bausch Health merger expected to close in Q3August 12, 2025 | msn.comDurect options imply 6.9% move in share price post-earningsAugust 12, 2025 | msn.comDURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on ...August 12, 2025 | gurufocus.comDURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch HealthAugust 12, 2025 | prnewswire.comSee More Headlines DRRX Stock Analysis - Frequently Asked Questions How were DURECT's earnings last quarter? DURECT Corporation (NASDAQ:DRRX) announced its earnings results on Tuesday, August, 12th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company earned $0.45 million during the quarter, compared to the consensus estimate of $0.32 million. DURECT had a negative net margin of 96.19% and a negative trailing twelve-month return on equity of 259.16%. When did DURECT's stock split? DURECT shares reverse split on the morning of Tuesday, December 6th 2022.The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE). Company Calendar Last Earnings8/12/2025Today5/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DRRX's financial health is in the Green zone, according to TradeSmith. DRRX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRRX CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.32 million Net Margins-96.19% Pretax Margin-416.01% Return on Equity-259.16% Return on Assets-71.78% Debt Debt-to-Equity RatioN/A Current Ratio0.98 Quick Ratio0.95 Sales & Book Value Annual Sales$1.66 million Price / Sales35.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book6.59Miscellaneous Outstanding Shares31,054,000Free Float30,060,000Market Cap$59.31 million OptionableOptionable Beta0.92 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:DRRX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
